## **European Respiratory Society Annual Congress 2012**

**Abstract Number: 4635** 

**Publication Number: 4710** 

**Abstract Group:** 7.2. Paediatric Asthma and Allergy

Keyword 1: Nitric oxide Keyword 2: Biomarkers Keyword 3: Asthma - diagnosis

Title: Exhaled nitric oxide in children with severe asthma

Dr. Jon 28393 Konradsen jon.konradsen@karolinska.se MD <sup>1,2</sup>, RN. Björn 28394 Nordlund bjorn.nordlund@karolinska.se <sup>1,2</sup>, Dr. Christophe 28395 Pedroletti christophe.pedroletti@akademiska.se MD <sup>3</sup>, Prof. Kjell 28396 Alving kjell.alving@kbh.uu.se <sup>3</sup> and Prof. Gunilla 28397 Hedlin gunilla.hedlin@ki.se MD <sup>1,2</sup>. <sup>1</sup> Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden ; <sup>2</sup> Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden and <sup>3</sup> Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden .

**Body:** Introduction: Exhaled nitric oxide (FE<sub>NO</sub>) is a biomarker of eosinophilic airway inflammation, but the relationship between FE<sub>NO</sub> and asthma severity is uncertain. We compared FE<sub>NO</sub> normalized against reference values (%FE<sub>NO</sub>) in children with Problematic severe (PA) and controlled (CA) asthma and investigated whether increased %FE<sub>NO</sub> is associated with morbidity, irrespective of predefined severity classification. Methods: Children with PA had recurrent symptoms despite treatment with ≥800 µg Budesonide, those with CA had few symptoms with 100-400 µg. The protocol included Asthma control test, spirometry (%), methacholine provocation (dose response slope), FE<sub>NO</sub> (p.p.b.), computerized tomography (CT) of the lungs (PA only) and blood sampling for eosinophils (109 x L<sup>-1</sup>) and IgE (kU/L). The difference between measured and expected  $FE_{NO}$  (Ln( $FE_{NO}$ ) = 0.0112 x height (cm) + 0.641) were given in percentages (%FE<sub>NO</sub>). Results: Children with PA (n=57, age 13y) had a trend towards higher levels of FE<sub>NO</sub> and %FE<sub>NO</sub> compared to children with CA (n=39, age 14y): 22 (10-40) vs. 17 (9-26), p=0.13 and 210% (101-367) vs. 139% (85-216), p=0.07, respectively. When analysing all children (n=96), those with %FE<sub>NO</sub>>200 had reduced asthma control (18.5 (17-20) vs. 20.4 (19-22), p=0.04) and FEV1/FVC (77 (74-81) vs. 83 (81-86), p=0.004) and increased bronchial hyperresponsiveness (54 (5-67) vs. 2 (0.4-36), p=0.001), bronchial wall thickening on CT (25 (21-29) vs. 17 (14-19), p=0.004), eosinophils (0.5 (0.4-0.6) vs. 0.3 (0.2-0.3), p<0.001) and IgE (539 (253-1525) vs. 140 (43-425), p<0.001) compared to those with %FE<sub>NO</sub><200. Conclusion: Children with high levels of %FE<sub>NO</sub> have increased morbidity which is partly independent of predefined severity classification.